Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4834)
All Articles published online
|
Publishing Process of This Article
|
Oct 14, 2018 (publication date) through Apr 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sato K, Uraoka T. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus. World J Gastroenterol 2018; 24(38): 4304-4310 [PMID: 30344416 DOI: 10.3748/wjg.v24.i38.4304] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v24/i38/4304.htm |
| Number | Citing Articles |
| 1 |
Joseph C. Ward, Sebastian Bowyer, Shucheng Chen, Guilherme Rodrigues Fernandes Campos, Santseharay Ramirez, Jens Bukh, Mark Harris. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon.
Journal of General Virology
2020; 101(11): 1182 doi: 10.1099/jgv.0.001486
|
| 2 |
Eiichi Ogawa, Norihiro Furusyo, Makoto Nakamuta, Hideyuki Nomura, Takeaki Satoh, Kazuhiro Takahashi, Toshimasa Koyanagi, Eiji Kajiwara, Kazufumi Dohmen, Akira Kawano, Aritsune Ooho, Koichi Azuma, Masaki Kato, Shinji Shimoda, Jun Hayashi. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, real‐world cohort study. Hepatology Research 2019; 49(6): 617 doi: 10.1111/hepr.13328
|
| 3 |
Atsushi Naganuma, Ken Sato, Toru Fukuchi, Masashi Namikawa, Satoru Kakizaki, Toshio Uraoka, Hiroshi Ohnishi, Hiroaki Okamoto. Successful prolonged treatment of glecaprevir/pibrentasvir for chronic hepatitis C patient with treatment failure after 8-week therapy: a case report. Clinical Journal of Gastroenterology 2019; 12(6): 592 doi: 10.1007/s12328-019-01029-y
|
| 4 |
C. Nelson Hayes, Michio Imamura, Junko Tanaka, Kazuaki Chayama. Road to elimination of HCV: Clinical challenges in HCV management. Liver International 2022; 42(9): 1935 doi: 10.1111/liv.15150
|
| 5 |
Xiaoqing Liu, Peng Hu. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection. Journal of Clinical and Translational Hepatology 2021; 0(000): 000 doi: 10.14218/JCTH.2020.00078
|